Special Issue

Advance in Transcriptional Regulation by Conventional Metabolic Enzymes

Message from the Guest Editor

Recently, many conventional metabolic enzymes are localized in nucleus, where they play novel non-conventional functions in nucleus including particularly transcriptional regulation through epigenetic modifications.

Pyruvate dehydrogenase complex (PDC) in nucleus can provide acetyl-coA, which is used for histone acetylation to regulate gene expression; Pyruvate kinase M2 (PKM2) in nucleus plays a conventional function to provide pyruvate, which is used for acetyl-CoA production to modify histone protein and a non-conventional function of protein kinase to phosphorylate histone protein and STAT3; Phosphofructokinase 1 (PFK1) binds to the transcriptional coactivator TEADS to stabilizes YAP/TAZ. PFK3B binds to Cdk1, cyclin D3 and Cdc25C. PFK1 product fructose-2,6-bisphosphate is used for the phosphorylation of p27 by Cdk1, undergoing p27 degradation.

In this Special Issue, we would like to publish new papers related to “Advance in Transcriptional Regulation by Conventional Metabolic Enzymes”.

- metabolic enzymes
- nuclear translocation
- transcriptional regulation
- epigenetic modification
- acetylation of DNA and histone
- methylation of DNA and histone

Guest Editor

Dr. Jae-Bong Park

Departmentn of Biochemistry, College of Medicine, Hallym University, Chuncheon, Kangwon-do, Republic of Korea

Deadline for manuscript submissions

closed (28 February 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/91555

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).